+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Asthmatics And COPD Drugs Global Market Report 2020

  • ID: 4852505
  • Report
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Abbott
  • Allergan
  • Boehringer Ingelheim Gmbh
  • GlaxoSmithKline
  • Mylan
  • Pfizer
  • MORE
Anti-Asthmatics And COPD Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global anti-asthmatics and copd drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the anti-asthmatics and copd drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Anti-Asthmatics And COPD Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Drug Class: Bronchodilators , Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs 2) By End User: Asthma Patients, COPD Patients 3) By Distribution Channel: Hospital Pharmacies , Private Clinics , Drug Stores , Retail Pharmacies , E-Commerce
  • Companies Mentioned: Novartis AG, Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh, AstraZeneca
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Allergan
  • Boehringer Ingelheim Gmbh
  • GlaxoSmithKline
  • Mylan
  • Pfizer
  • MORE
1. Executive Summary

2. Anti-Asthmatics And COPD Drugs Market Characteristics

3. Anti-Asthmatics And COPD Drugs Market Size And Growth
3.1. Global Anti-Asthmatics And COPD Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Anti-Asthmatics And COPD Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Anti-Asthmatics And COPD Drugs Market Segmentation
4.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
Bronchodilators
  • Anti-inflammatory Drugs
  • Monoclonal Antibodies
  • Combination Drugs
4.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Asthma Patients
  • COPD Patients
4.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce
5. Anti-Asthmatics And COPD Drugs Market Regional And Country Analysis
5.1. Global Anti-Asthmatics And COPD Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Anti-Asthmatics And COPD Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Anti-Asthmatics And COPD Drugs Market
6.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
6.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Anti-Asthmatics And COPD Drugs Market
7.1. China Anti-Asthmatics And COPD Drugs Market Overview
7.2. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Anti-Asthmatics And COPD Drugs Market
8.1. India Anti-Asthmatics And COPD Drugs Market Overview
8.2. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Anti-Asthmatics And COPD Drugs Market
9.1. Japan Anti-Asthmatics And COPD Drugs Market Overview
9.2. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Anti-Asthmatics And COPD Drugs Market
10.1. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Anti-Asthmatics And COPD Drugs Market
11.1. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Anti-Asthmatics And COPD Drugs Market
12.1. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Anti-Asthmatics And COPD Drugs Market
13.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
13.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Anti-Asthmatics And COPD Drugs Market
14.1. UK Anti-Asthmatics And COPD Drugs Market Overview
14.2. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Anti-Asthmatics And COPD Drugs Market
15.1. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Anti-Asthmatics And COPD Drugs Market
16.4. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Anti-Asthmatics And COPD Drugs Market
17.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
17.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Anti-Asthmatics And COPD Drugs Market
18.1. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Anti-Asthmatics And COPD Drugs Market
19.1. North America Anti-Asthmatics And COPD Drugs Market Overview
19.2. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Anti-Asthmatics And COPD Drugs Market
20.1. USA Anti-Asthmatics And COPD Drugs Market Overview
20.2. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Anti-Asthmatics And COPD Drugs Market
21.1. South America Anti-Asthmatics And COPD Drugs Market Overview
21.2. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Anti-Asthmatics And COPD Drugs Market
22.1. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Anti-Asthmatics And COPD Drugs Market
23.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
23.2. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Anti-Asthmatics And COPD Drugs Market
24.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
24.2. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Anti-Asthmatics And COPD Drugs Market Competitive Landscape And Company Profiles
25.1. Anti-Asthmatics And COPD Drugs Market Competitive Landscape
25.2. Anti-Asthmatics And COPD Drugs Market Company Profiles
25.2.1. Novartis AG
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Merck & Co
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. GlaxoSmithKline
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Boehringer Ingelheim Gmbh
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. AstraZeneca
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market

27. Anti-Asthmatics And COPD Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Anti-Asthmatics And COPD Drugs Market Future Outlook and Potential Analysis

30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Allergan
  • Boehringer Ingelheim Gmbh
  • GlaxoSmithKline
  • Mylan
  • Pfizer
  • MORE
The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.

The global anti-asthmatics and copd drugs market was valued at about $33.4 billion in 2018 and is expected to grow to $42.01 billion at a CAGR of 5.9% through 2022.

North America was the largest region in the anti-asthmatics and COPD drugs market in 2017.

Modifiable risk factors including smoking, lack of physical exercise, and unhealthy eating habits drive the Asthma and COPD drugs market. Even though there is a decreasing trend of smoking prevalence globally, developing countries such as China, India, Indonesia, and Nigeria among others have increasing smoking prevalence. For instance, the number of tobacco smokers is set to increase by 24 million in Indonesia and by 7 million in Nigeria from 2015 to 2025, and more than 40% of global cigarette consumption is concentrated in China. Consumption of fats including saturated fatty acids which is a risk factor for Asthma and COPD is more in high income countries including USA and Europe. According to WHO, in developed countries more than 35% of total energy requirement is derived from fats when compared to < 20% in low income countries, and < 25% in lower middle income countries.

Increasing patent expiration of innovator drugs is restraining the anti-asthamatics and COPD drug market. Due to patent expiration, generic drugs are entering the market which are inexpensive when compared to innovator drugs. For example, patent for Advair Diskus inhaler by GSK has expired in 2016, and many players including Novartis, Hikama, and Mylan are trying to get FDA approval for a generic version of the innovator drug.

The use of combination drugs for the treatment of asthma and COPD is increasing. This is due to the greater impact on patient reported outcomes (PROs) compared to monotherapies. For example, combination of short acting beta agonists (SABA) and short acting muscarinic antagnoists (SAMA) are superior compared to either medication alone in improving lung function. The use of combination long acting beta agonists (LABA), and long acting muscarnic antagonists (LAMA) have improved lung function than long acting monotherapy bronchodilators.

Many inhalers that do not use chlorofluorocarbons (CFC) are already available for the treatment of asthma and chronic obstructive pulmonary disease. These products aren't necessarily ""official"" direct alternatives to CFC Metered Dose Inhalers, but may in many patients serve as a useful medication that could replace the need for a particular CFC Metered Dose Inhaler. FDA will determine official alternatives by using the criteria established through notice-and-comment rulemaking.

Major players in the market are Novartis AG, Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh and AstraZeneca.
Note: Product cover images may vary from those shown
5 of 5
  • Novartis AG
  • Merck & Co
  • GlaxoSmithKline
  • Boehringer Ingelheim Gmbh
  • AstraZeneca
  • Roche
  • Teva Pharmaceutical
  • Vectura
  • Pfizer
  • Abbott
  • Mylan
  • Allergan
  • Cipla
  • Akorn
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll